×

Ekso Bionics® To Showcase First FDA Cleared Exoskeleton Approved for Use with Stroke Patients at 9th World Congress for NeuroRehabilitation (WCNR)

RICHMOND, Calif., May 10, 2016 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (OTCQB:EKSOD), a robotic exoskeleton company, today announced that it will be attending the 9th World Congress for NeuroRehabilitation (WCNR), taking place May 10-13, 2016 in Philadelphia, PA.

During the conference, the company will be featuring live demonstrations of its Ekso GT™ robotic exoskeleton, the first and only robotic exoskeleton FDA cleared for use in the treatment of individuals with hemiplegia due to stroke, and individuals with spinal cord injuries at levels L5-C7*. With this clearance, clinics using the Ekso GT are able to offer exoskeleton therapy to the widest patient population among all exoskeletons on the market.

Ekso GT is a wearable robotic suit, or exoskeleton, that enables people with paralysis of the lower limbs due to stroke or spinal cord injury to stand up and walk over ground. The Ekso GT with smart VariableAssist™ software is the only exoskeleton available for rehabilitation institutions that can provide adaptive amounts of power to either side of the patient’s body, challenging the patient as they progress through their continuum of care. The suit’s patented technology provides physical therapists the ability to mobilize patients earlier, more frequently and with a greater number of high intensity steps.

*for full indications for use please visit www.eksobionics.com

About Ekso Bionics®
Ekso Bionics is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical, industrial and defense applications. Founded in 2005, the company continues to build upon its unparalleled expertise to design some of the most cutting-edge, innovative wearable robots available on the market. They are the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe, to providing research for the advancement of R&D projects intended to benefit U.S. defense capabilities.

The company is headquartered in the Bay Area and is listed on the OTCQB under the symbol EKSOD. For more information, visit: www.eksobionics.com.

Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) a projection of financial results, financial condition, capital expenditures, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing to fund the Company's operations and necessary to develop or enhance our technology, the significant length of time and resources associated with the development of the Company's products, the Company's failure to achieve broad market acceptance of the Company's products, the failure of our sales and marketing organization or partners to market our products effectively, adverse results in future clinical studies of the Company's medical device products, the failure to obtain or maintain patent protection for the Company's technology, failure to obtain or maintain regulatory approval to market the Company's medical devices, lack of product diversification, existing or increased competition, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. To learn more about Ekso Bionics please visit us at www.eksobionics.com. The Company does not undertake to update these forward-looking statements.

Media Contacts: Ekso Bionics Heidi Darling Director of Marketing Communications 510-984-1761 x317 hdarling@eksobionics.com Investor Contact: Debbie Kaster 415-937-5403 investors@eksobionics.com

Source:Ekso Bionics